On April 1, 2025 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, held from April 25 – 30, 2025 (Press release, Revolution Medicines, APR 1, 2025, View Source [SID1234651723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.

Details of the abstracts are listed below:

Revolution Medicines Oral Presentations:

Title: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors
Presenter: Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number: CT019
Session: New Frontiers in Precision Oncology
Date/Time: April 27; 5:00 p.m. – 5:15 p.m. CST

Title: Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor
Presenter: Anne Edwards, Ph.D.
Abstract Number: ND06
Session: New Drugs on the Horizon: Part 2
Date/Time: April 27; 3:25 p.m. – 3:40 p.m. CST

Revolution Medicines Poster Presentations:

Title: Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
Presenter: Jia Luo, M.D., Dana-Farber Cancer Institute
Abstract Number: LB218
Session: Late-Breaking Research: Clinical Research 1
Date/Time: April 28; 2:00 p.m. – 5:00 p.m. CST

Title: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies
Presenter: Mallika Singh, Ph.D.
Abstract Number: LB281
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time: April 29; 9:00 a.m. – 12:00 p.m. CST

Title: Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy
Presenter: Mariela Moreno Ayala, Ph.D.
Abstract Number: 6046
Session: Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Collaborator Presentations

Title: Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models
Presenter: Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number: LB293
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time: April 29; 9:00 a.m. – 12:00 p.m. CST

Title: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation
Presenter: Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center
Abstract Number: 5512
Session: Drug Resistance in Molecular Targeted Therapies 3
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC
Presenter: Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number: 5336
Session: CDK Inhibitors
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma
Presenter: Jingjing Jiang, Ph.D.
Abstract Number: 5691
Session: Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer
Presenter: Joshua H. Choe, Dana-Farber Cancer Institute
Abstract Number: 5507
Session: Drug Resistance in Molecular Targeted Therapies 3
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC
Presenter: Margo I. Orlen, Penn Medicine
Abstract Number: 6405
Session: Checkpoints and Modulators of Tumor Microenvironment
Date/Time: April 29; 3:25 p.m. – 3:40 p.m. CST

On April 1, 2025 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, reported that the Company’s CEO, Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7, 2025 (Press release, Purple Biotech, APR 1, 2025, View Source [SID1234651722]). The panel titled "New Radiotherapy and Targeted Therapy Approaches" will take place from 2:00 PM to 2:50 PM ET. Management will also participate in 1×1 meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 1, 2025 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, reported that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025 (Press release, Precision Biosciences, APR 1, 2025, View Source [SID1234651721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Date: Monday, April 7, 2025
Time: 3:00 PM ET in Track 2
Format: Presentation
Webcast Registration: Link

A live webcast will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.

On April 1, 2025 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, reported its participation in the following investor conference (Press release, Nkarta, APR 1, 2025, View Source [SID1234651720]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

24th Annual Needham Virtual Healthcare Conference
April 8, 2025
11:00 a.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

On April 1, 2025 US NCI reported new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancersExit Disclaimer, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH) (Press release, US NCI, APR 1, 2025, View Source [SID1234651719]). The findings, published April 1, 2025, in Nature Medicine, offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This form of therapy involves identifying and selecting immune cells (TILs) that are found in the tumor that specifically recognize and attack a patient’s tumor cells. Next, scientists grow those TILs into large quantities in the laboratory before they are finally administered to the patient.

Patients in the clinical trial, who had a variety of gastrointestinal tumors, also received the immune checkpoint inhibitor pembrolizumab (Keytruda) to help further boost their immune response. The result was nearly 24% of patients treated with selected TILs plus pembrolizumab had a substantial reduction in the size of their tumors, compared with 7.7% of patients who received selected TILs without pembrolizumab. Patients treated with TILs that had not been selected for anti-tumor activity had no tumor shrinkage.

"We’re seeing the first extension of cellular therapy with TILs into the common solid cancers," said Steven A. Rosenberg, M.D., Ph.D., the study’s lead investigator at NIH’s National Cancer Institute. "We see a little crack in the solid wall of cancer by using cell-based immunotherapy for the common solid cancers, and we think we have ways to open that crack even further."

The clinical trial included 91 patients with metastatic gastrointestinal cancers—including esophageal, stomach, pancreatic, colon, and rectal cancers—that had worsened despite a median of four prior treatment regimens. In the pilot phase of the trial, 18 patients were treated with TILs that had not been selected for anti-tumor activity, and there were no objective responses (tumor shrinkage of at least 30% is considered an objective response). In the second phase, 39 patients were treated with selected TIL therapy, and three (7.7%) had objective responses.

In the third phase, 34 patients received pembrolizumab immediately before selected TIL therapy to prevent the newly introduced immune cells from becoming inactivated by the patient’s own immune system. This group had the best response, with 8 of 34 (23.5%) patients experiencing an objective response. All 91 patients had also received standard chemotherapy and high-dose interleukin-2 before the TIL therapy.

In the trial’s second and third phases, objective responses were seen in multiple types of gastrointestinal cancers, including cancers of the colon, rectum, pancreas, and bile duct. Responses lasted between 8 months and more than 5.8 years in the group that received selected TIL therapy alone, and between 4 months and 3.5 years in the group that received selected TIL therapy and pembrolizumab. Serious side effects occurred in 30% of patients treated with selected TILs.

The researchers are now developing methods to identify TILs that recognize multiple, specific proteins within a tumor, known as neoantigens, to help increase the number of patients who respond to selected TIL therapy with pembrolizumab.

TIL therapy, developed in the late 1980s by Dr. Rosenberg and his colleagues at NIH, uses an individual’s own TILs to fight their tumor cells. Last year, the Food and Drug Administration approved the first TIL therapy for a solid cancer, lifileucel (Amtagvi), for treating advanced melanoma.